CHEMOKINE RECEPTORS CCR1 AND CCR2 ARE UP-REGULATED ON CIRCULATING LEUKEMIC CELLS OF THE UNTREATED CD38+ CLL PATIENTS WITH THE HIGH EBV DNA-COPY LOAD

Research output: Contribution to conferenceAbstractpeer-review

Abstract

AIM:BACKGROUND AND Chronic lymphocytic leukemia (CLL) is frequently complicated due to immune deregulation and concomitant infections. The high EBV DNA-load had been associated with poor overall survival and disease aggressiveness in CLL patients. Eelier, we demonstrated that CCR1 and CCR2 were up-regulated in peripheral blood (PB) B cells upon in vitro EBV infection.
METHODS:We have measured the EBV DNA-copy numbers in the PB mononuclear cells (PBMC) of 61 newly diagnozed CLL patients, and assessed by polychromatic flow cytometry the cell-surface expression of CCR1, CCR2, and the established negative predictor CD38 in order to estimate correlations.
RESULTS:The positive correlations have been revealed between the presence of CD38 and CCR1 or CCR2 on leukemic cells. Moreover, these three indicators negatively correlated with the frequency of the leukemic cells within the PBMC as well as WBC sets. More than 200 EBV DNA copies per 105 cells were determined in 3 patients only; two of them presented 30% of the CD38+ leukemic cells. We didn’t detect EBNA2 or LMP1 mRNA expression in PBMC of these 3 EBV-positive patients, using real-time RT-PCR. Notably, in the EBV/CD38-positive patients, both CCR1 and CCR2 were highly expressed on the leukemic cells (>20%).
CONCLUSIONS:Migration of the CCR1- and CCR2-expressing leukemic cells from circulation into the secondary lymphoid organs may contribute to aggressive pathogenesis of CLL. The association studies would verify whether the CCR1/CCR2 expression on circulating leukemic cells is a reliable negative predictor in CLL.
SOURCES OF FUNDING:This research was funded by the Latvian Council of Science projects No. 651/2014 and No. lzp-2018/1-0156.
Original languageEnglish
Pages210
Number of pages1
Publication statusPublished - 15 Sep 2021
Event23rd Annual Conference of the European Society for Clinical Virology - Manchester, United Kingdom
Duration: 15 Sep 202118 Sep 2021
Conference number: 23
https://www.escv2021.org/conference-information/about-escv/
https://healthmanagement.org/c/hospital/event/23rd-annual-conference-of-the-european-society-for-clinical-virology

Conference

Conference23rd Annual Conference of the European Society for Clinical Virology
Abbreviated titleESCV 2021
Country/TerritoryUnited Kingdom
CityManchester
Period15/09/2118/09/21
Internet address

Keywords*

  • CLL, EBV, CD38, CCR1, CCR2

Field of Science*

  • 1.6 Biological sciences
  • 3.2 Clinical medicine

Publication Type*

  • 3.4. Other publications in conference proceedings (including local)

Fingerprint

Dive into the research topics of 'CHEMOKINE RECEPTORS CCR1 AND CCR2 ARE UP-REGULATED ON CIRCULATING LEUKEMIC CELLS OF THE UNTREATED CD38+ CLL PATIENTS WITH THE HIGH EBV DNA-COPY LOAD'. Together they form a unique fingerprint.

Cite this